| Detected | Trial | Change |
|---|---|---|
| 2026-05-19 | NCT07095452 A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous… |
Trial sites expanded: 39 -> 43 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-20 | NCT07600151 Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | Phase 1/2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06158841 | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard… | Multiple Myeloma | Recruiting |
| Phase 2/3 | |||
| NCT07095452 | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous… | Multiple Myeloma | Recruiting |
| Phase 1/2 | |||
| NCT06892522 | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult… | Multiple Myeloma | Recruiting |
| NCT06158854 | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult… | Immunoglobulin Light Chain (AL) Amyloidosis | Recruiting |
| NCT03933735 | A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | Active, Not Recruiting |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | Recurrent Waldenstrom Macroglobulinemia | Not Yet Recruiting |
| NCT07600151 | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | Myeloma Multiple | Not Yet Recruiting |
| Phase 1 | |||
| NCT06896916 | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3… | Multiple Myeloma | Recruiting |
| NCT05650632 | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in… | Multiple Myeloma | Recruiting |